SAN DIEGO, California — September 16, 2025 — Leads & Copy — Bionano Genomics, Inc. (NASDAQ: BNGO) has announced the pricing of a public offering consisting of 5,000,000 shares of common stock (or equivalents), Series E warrants, and short-term Series F warrants, at a combined price of $2.00 per share and accompanying warrants. The offering is expected to close around September 17, 2025, subject to customary conditions.
The Series Warrants will have an exercise price of $2.00 per share and are immediately exercisable upon issuance. The Series E warrants expire five years from issuance, while the Series F warrants expire after eighteen months. H.C. Wainwright & Co. is the exclusive placement agent.
The company anticipates gross proceeds of approximately $10 million from the offering, before deducting fees and expenses. An additional $20 million could be generated if the Series Warrants are fully exercised. Bionano plans to use the net proceeds for working capital and general corporate purposes.
These securities are offered via a registration statement on Form S-1, declared effective by the SEC on September 16, 2025. The offering is made through a prospectus, available on the SEC’s website and from H.C. Wainwright & Co., LLC.
This announcement is not an offer to sell or a solicitation to buy securities, nor will there be any sale in jurisdictions where such actions are unlawful.
Erik Holmlin, CEO of Bionano Genomics, Inc. can be reached at +1 (858) 888-7610 or eholmlin@bionano.com.
Source: Bionano
